TABLE 3.
Comparison of HPV-Risk assay and HC2 for HPV detection stratified by clinical outcomea
CIN grade | HPV-Risk assay result | No. of women with the indicated HC2 result |
|||||
---|---|---|---|---|---|---|---|
Total study group |
Women ≥30 yr old |
||||||
Positive | Negative | Total | Positive | Negative | Total | ||
CIN3+ | Positive | 78 | 2 | 80 | 62 | 2 | 64 |
Negative | 2 | 0 | 2 | 2 | 0 | 2 | |
Total | 80 | 2 | 82 | 64 | 2 | 66 | |
CIN2+ | Positive | 117 | 2 | 119 | 89 | 2 | 91 |
Negative | 5 | 3 | 8 | 5 | 2 | 7 | |
Total | 122 | 5 | 127 | 94 | 4 | 98 | |
≤CIN1 | Positive | 87 | 10 | 97 | 47 | 10 | 57 |
Negative | 33 | 1,059 | 1,092 | 27 | 906 | 933 | |
Total | 120 | 1,069 | 1,189 | 74 | 916 | 990 |
HPV, human papillomavirus; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; ≤CIN1, cervical intraepithelial neoplasia grade 1 or lower, i.e., women with two consecutive negative cytology results (control group).